CONMED Corporation
13
6
6
4
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
High Risk
Score: 75/100
23.1%
3 terminated/withdrawn out of 13 trials
57.1%
-29.4% vs industry average
8%
1 trials in Phase 3/4
50%
2 of 4 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (13)
BioBrace® Implant for Arthroscopic Repair of Full Thickness Rotator Cuff Tears
Role: lead
BioBrace® Augmentation in Anterior Cruciate Ligament Reconstruction Procedures
Role: lead
Effects of a Goal-directed Hemodynamic Therapy Driven by ECOM on Morbidity and Mortality After Cardiac Surgery?
Role: collaborator
BioBrace® in Arthroscopic Brostrom Lateral Ankle Ligament Repair
Role: collaborator
Biologic Augment of the Medial Patellofemoral Ligament Following Primary Lateral Patellofemoral Dislocation (BioPPD)
Role: collaborator
Maximal Repair Versus Bridging Reconstruction with BioBrace®
Role: collaborator
SHould You TransFer the Tubercle?
Role: collaborator
Impedance Cardiography: Clinical Evaluation of Endotracheal Cardiac Output Monitor (ECOM)
Role: collaborator
Comparison of Pneumoinsufflation Modes and Pressure Settings in Gynecology
Role: collaborator
ConMed Beamer Study
Role: collaborator
Ultralow Versus Standard Pneumoperitoneum Pressure
Role: collaborator
Pneumoperitoneum Management With Low vs. Higher Pressure
Role: collaborator
Endotracheal Cardiac Output Monitor (ECOM) for Patients Undergoing Liver Transplantation
Role: collaborator
All 13 trials loaded